Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo

8 Jun 2024

Abstract excerpt

BACKGROUND: Inhibiting ENaC in the airways of people with cystic fibrosis (pwCF) is hypothesized to enhance mucociliary clearance (MCC) and provide clinical benefit. Historically, inhaled ENaC blockers have failed to show benefit in pwCF challenging this hypothesis. It is however unknown whether the clinical doses were sufficient to provide the required long duration of action in the lungs and questions whether a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis Research Advances
Share to Inhalation and Respiratory Drug Delivery
Share to Neonatal Respiratory Health Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38851923
DOI: 10.1016/j.jcf.2024.06.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivoPMID 38851923Read ↗

Computational Fluid Particle Dynamics-Informed Machine Learning Prototype for a User-Centered Smart Inhaler Enabling Uniform Drug Delivery to Small AirwaysSemantic proximity Read ↗

Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesiaSemantic proximity Read ↗

Advances in the Cystic Fibrosis Drug Development PipelineSemantic proximity Read ↗

Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis.Semantic proximity Read ↗

Chronic obstructive pulmonary disease: diagnosis and treatment of stable phase of disease; personalized treatment approach using phenotype features of the disease Summary of the 2020-2021 Czech Pneumological and Phthiseological Society position paper.Semantic proximity Read ↗

Cystic fibrosis year in review 2021.Semantic proximity Read ↗

A retrospective analysis of clinical parameters, safety and tolerability of Elexacaftor/Tezacaftor/Ivacaftor in a cohort of patients aged 6-17 years with cystic fibrosisSemantic proximity Read ↗

Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.